Khattak, Muhammad ALuke, Jason JLong, Georgina VAscierto, Paolo ARutkowski, PiotrSchadendorf, DirkRobert, CarolineGrob, Jean-Jacquesde la Cruz Merino, LuisDel Vecchio, MicheleSpagnolo, FrancescoMackiewicz, JacekChiarion-Sileni, VannaCarlino, Matteo SMohr, PeterDe Galitiis, FedericaRoss, Merrick IEroglu, ZeynepChen, KeJiang, RuixuanFukunaga-Kalabis, MizuhoKrepler, ClemensEggermont, Alexander M MKirkwood, John M2023-05-032023-05-032022-10-03http://hdl.handle.net/10668/22180Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients ≥12 to The HRQoL population included 969 patients (pembrolizumab, n = 483; placebo, n = 486). Compliance at week 48 was ≥80% for both instruments. EORTC QLQ-C30 GHS/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores were stable from baseline to week 48 in both arms, with no clinically meaningful decline observed. Scores did not differ significantly between pembrolizumab and placebo. EORTC QLQ-C30 GHS/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores remained stable through week 96 in both arms. HRQoL was stable with adjuvant pembrolizumab, with no clinically meaningful decline observed. Change from baseline in HRQoL was similar between arms. These results, in conjunction with the improved RFS and manageable safety previously reported, support the use of adjuvant pembrolizumab for high-risk stage II melanoma.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AdjuvantImmunotherapyMelanomaPatient-reported outcomesPembrolizumabHumansQuality of LifeNeoplasm Recurrence, LocalMelanomaAdjuvants, Immunologicresearch article36202690open access10.1016/j.ejca.2022.08.0041879-0852http://www.ejcancer.com/article/S0959804922004774/pdf